Virpax Pharmaceuticals Inc.
13F holders, Q2 2024 (June 30)7holders +2
3new positions
1sold out
$0.52avg. 13F price*
At the end of Q2 2024, 7 institutions reported holding Virpax Pharmaceuticals Inc. in their 13F filings, up 2 from Q1 2024. 3 opened new positions and 1 sold out. The largest holders were Warberg Asset Management LLC ($10K), Tower Research Capital LLC (TRC) ($2K) and UBS Group AG ($562).
- Company
- Virpax Pharmaceuticals Inc.
- CUSIP
- 928251206
- Latest filing quarter
- Q4 2024
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $11K |
| Exits | 1 | $34 |
All 13F filers, Q1 2024 → Q2 2024: 22,791 shares bought and 458 shares sold, net +22,333 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 7 holders
| Warberg Asset Management LLC | 0.05% | New | 20,000 | $10K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +117.1% | 3,146 | $2K |
| UBS Group AG | 0.00% | New | 1,087 | $562 |
| Signature Resources Capital Management, LLC | 0.00% | Reduce -90.0% | 50 | $26 |
| Morgan Stanley | 0.00% | No change | 15 | $8 |
| Bank of America Corp. | 0.00% | New | 7 | $4 |
| Hantz Financial Services, Inc. | 0.00% | No change | 10 | $0 |
"% of holder's portfolio" is VIRPAX PHARMACEUTICALS INC's weight in each manager's 13F, not the share of Virpax Pharmaceuticals Inc. the manager owns.